Opinion

Video

The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Related Videos
A panel of 4 experts on PNH
A panel of 4 experts on PNH
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
A panel of 4 experts on biosimilars
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 5 experts on RSV
A panel of 5 experts on RSV
Related Content
CH LogoCenter for Biosimilars Logo